Case Report: Nintedanib for Pembrolizumab-Related Pneumonitis in a Patient With Non-Small Cell Lung Cancer

被引：10
作者：
Xie, Xiao-Hong [1 ]
Deng, Hai-Yi [1 ]
Lin, Xin-Qing [1 ]
Wu, Jian-Hui [1 ]
Liu, Ming [1 ]
Xie, Zhan-Hong [1 ]
Qin, Yin-Yin [1 ]
Zhou, Cheng-Zhi [1 ]
机构：
[1] Guangzhou Med Univ, Affiliated Hosp 1, Natl Clin Res Ctr Resp Dis, Stale Key Lab Resp Dis,Guangzhou Inst Resp Hlth, Guangzhou, Peoples R China
来源：
FRONTIERS IN ONCOLOGY | 2021年 / 11卷
关键词：
checkpoint inhibitor-related pneumonitis; nintedanib; steroid therapy; non-small cell lung cancer; pembrolizumab; IMMUNOTHERAPY;
D O I：
10.3389/fonc.2021.673877
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Pembrolizumab, an immune checkpoint inhibitor (ICI) approved for advanced non-small cell lung cancer (NSCLC) treatment, has shown superior survival benefits. However, pembrolizumab may lead to severe immune-related adverse events (irAEs), such as checkpoint inhibitor-related pneumonitis (CIP). The routine treatment of CIP was based on systemic corticosteroids, but the therapies are limited for patients who are unsuitable for steroid therapy. Here, we present the first successful treatment of nintedanib for pembrolizumab-related pneumonitis in a patient with advanced NSCLC.
引用
收藏
页数：4
相关论文
共 18 条
  • [1] VEGF (Vascular Endothelial Growth Factor) and Fibrotic Lung Disease
    Barratt, Shaney L.
    Flower, Victoria A.
    Pauling, John D.
    Millar, Ann B.
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2018, 19 (05)
  • [2] Nintedanib Effect in Osimertinib-Induced Interstitial Pneumonia
    Fang, Wenfeng
    Huang, Yihua
    Gan, Jiadi
    He, Bishan
    Zhang, Li
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2020, 15 (03) : E34 - E35
  • [3] Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
    Fukurnura, Dal
    Kloepper, Jonas
    Amoozgar, Zohreh
    Duda, Dan G.
    Jain, Rakesh K.
    [J]. NATURE REVIEWS CLINICAL ONCOLOGY, 2018, 15 (05) : 325 - 340
  • [4] BIBF 1120: Triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy
    Hilberg, Frank
    Roth, Gerald J.
    Krssak, Martin
    Kautschitsch, Susanna
    Sommergruber, Wolfgang
    Tontsch-Grunt, Ulrike
    Garin-Chesa, Pilar
    Bader, Gerd
    Zoephel, Andreas
    Quant, Jens
    Heckel, Armin
    Rettig, Wolfgang J.
    [J]. CANCER RESEARCH, 2008, 68 (12) : 4774 - 4782
  • [5] PD-Loma: a cancer entity with a shared sensitivity to the PD-1/PD-L1 pathway blockade
    Hirsch, Laure
    Zitvogel, Laurence
    Eggermont, Alexander
    Marabelle, Aurelien
    [J]. BRITISH JOURNAL OF CANCER, 2019, 120 (01) : 3 - 5
  • [6] Utility of KL-6/MUC1 in the clinical management of interstitial lung diseases
    Ishikawa, Nobuhisa
    Hattori, Noboru
    Yokoyama, Akihito
    Kohno, Nobuoki
    [J]. RESPIRATORY INVESTIGATION, 2012, 50 (01) : 3 - 13
  • [7] Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy
    Naidoo, Jarushka
    Wang, Xuan
    Woo, Kaitlin M.
    Iyriboz, Tunc
    Halpenny, Darragh
    Cunningham, Jane
    Chaft, Jamie E.
    Segal, Neil H.
    Callahan, Margaret K.
    Lesokhin, Alexander M.
    Rosenberg, Jonathan
    Voss, Martin H.
    Rudin, Charles M.
    Rizvi, Hira
    Hou, Xue
    Rodriguez, Katherine
    Albano, Melanie
    Gordon, Ruth-Ann
    Leduc, Charles
    Rekhtman, Natasha
    Harris, Bianca
    Menzies, Alexander M.
    Guminski, Alexander D.
    Carlino, Matteo S.
    Kong, Benjamin Y.
    Wolchok, Jedd D.
    Postow, Michael A.
    Long, Georgina V.
    Hellmann, Matthew D.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (07) : 709 - +
  • [8] Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
    Reck, Martin
    Rodriguez-Abreu, Delvys
    Robinson, Andrew G.
    Hui, Rina
    Csoszi, Tibor
    Fulop, Andrea
    Gottfried, Maya
    Peled, Nir
    Tafreshi, Ali
    Cuffe, Sinead
    O'Brien, Mary
    Rao, Suman
    Hotta, Katsuyuki
    Leiby, Melanie A.
    Lubiniecki, Gregory M.
    Shentu, Yue
    Rangwala, Reshma
    Brahmer, Julie R.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (19) : 1823 - 1833
  • [9] Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial
    Reck, Martin
    Kaiser, Rolf
    Mellemgaard, Anders
    Douillard, Jean-Yves
    Orlov, Sergey
    Krzakowski, Maciej
    von Pawel, Joachim
    Gottfried, Maya
    Bondarenko, Igor
    Liao, Meilin
    Gann, Claudia-Nanette
    Barrueco, Jose
    Gaschler-Markefski, Birgit
    Novello, Silvia
    [J]. LANCET ONCOLOGY, 2014, 15 (02) : 143 - 155
  • [10] Therapeutic impact of Nintedanib with paclitaxel and/or a PD-L1 antibody in preclinical models of orthotopic primary or metastatic triple negative breast cancer
    Reguera-Nunez, Elaine
    Xu, Ping
    Chow, Annabelle
    Man, Shan
    Hilberg, Frank
    Kerbel, Robert S.
    [J]. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2019, 38 (1)
12